Pathogenic Th17 cell-mediated liver fibrosis contributes to resistance to PD-L1 antibody immunotherapy in hepatocellular carcinoma
International Immunopharmacology · 2024-03 · 129 · 111601
DOI: 10.1016/j.intimp.2024.111601 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024-03. Verfasst von Meiying Song und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Medical College of Qingdao University, Qingdao, Shandong 266071, PR China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Shandong Province Natural Science Foundation, Natural Science Foundation of Qingdao.
Abstract (Originalsprache)
Understanding the mechanisms of resistance of hepatocellular carcinoma (HCC) to targeted therapies and immune checkpoint blockade is critical for the development of new combination therapies and improving patient survival. Here, we found that in HCC, anti-programmed cell death 1 ligand 1 (PD-L1) therapy reduces liver cancer growth, but the tumors eventually become resistant to continued therapy. Experimental analyses shows that the infiltration of pathogenic T helper 17 (pTh17) cells increases in drug-resistant HCC, and pTh17 cells secrete interleukin-17A (IL-17A), which promotes the expression of PD-L1 on the surface of HCC cells and produces resistance to anti-PD-L1 therapy. Anti-IL-17A combined with PD-L1 blockade significantly increased the infiltration of cytotoxic CD8+ T cells expressing high levels of interferon-γ and reduced treatment resistance in HCC. These results support the combination of anti-PD-L1 and anti-IL-17A as a novel strategy to induce effective T cell-mediated anti-tumor immune responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Medical College of Qingdao University, Qingdao, Shandong 266071, PR China.
- Division of Hepatology, Liver Disease Center, Organ Transplantation Center, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266071, PR China.
- School of Emergency Medicine, Medical College of Qingdao University, Qingdao, Shandong 266071, PR China.
- Department of Special Medicine, School of Basic Medical College, Qingdao University, Qingdao, Shandong 266071, PR China.
- Department of Clinical Medicine, Medical College of Qingdao University, Qingdao, Shandong 266071, PR China.
- Department of Immunology, Medical College of Qingdao University, Qingdao, Shandong 266071, PR China. Electronic address: zhangbei124@aliyun.com.
Förderung
- Shandong Province Natural Science Foundation
- Natural Science Foundation of Qingdao
Zitieren
APA
Song, M., Wang, L., Jiang, S., Liang, J., Li, W., Rao, W., Du, Q., Liu, G., Meng, H., Tang, L., Li, Z., Yang, Y., Zhang, L., & Zhang, B. (2024). Pathogenic Th17 cell-mediated liver fibrosis contributes to resistance to PD-L1 antibody immunotherapy in hepatocellular carcinoma. International Immunopharmacology, 129, 111601. https://doi.org/10.1016/j.intimp.2024.111601
Vancouver
Song M, Wang L, Jiang S, Liang J, Li W, Rao W, et al. Pathogenic Th17 cell-mediated liver fibrosis contributes to resistance to PD-L1 antibody immunotherapy in hepatocellular carcinoma. International Immunopharmacology. 2024;129:111601. doi:10.1016/j.intimp.2024.111601
BibTeX
@article{Song2024,
author = {Song, Meiying and Wang, Luoyang and Jiang, Suli and Liang, Jie and Li, Wei and Rao, Wei and Du, Qiaochu and Liu, Guixian and Meng, Haining and Tang, Lei and Li, Zhifei and Yang, Yanyan and Zhang, Li and Zhang, Bei},
title = {Pathogenic Th17 cell-mediated liver fibrosis contributes to resistance to PD-L1 antibody immunotherapy in hepatocellular carcinoma},
journal = {International Immunopharmacology},
year = {2024},
volume = {129},
pages = {111601},
doi = {10.1016/j.intimp.2024.111601}
}
EUVIMED